Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can eye drops offer a new way to treat fuchs dystrophy?

NCT ID NCT05376176

Disease control Sponsor: Santen Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This clinical trial is testing whether an investigational eye drop called STN1010904 can improve vision in people with Fuchs endothelial corneal dystrophy (FECD), a condition that damages the cornea's inner layer and can lead to blurry vision. The study will compare two different strengths of the eye drop against a placebo (inactive solution) in about 86 adults with FECD. Participants will use the assigned eye drops twice daily for 18 months, and researchers will measure changes in visual acuity and contrast sensitivity to see if the treatment helps.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
STN1010904 ophthalmic suspension (eye drops)
What this could lead to
If successful, this could lead to a non-surgical treatment option for Fuchs endothelial corneal dystrophy, potentially delaying or avoiding the need for corneal transplant surgery.
What could go wrong
This is an early-phase (IIa) study with a small number of participants, so results may not be conclusive. The eye drops may not improve vision significantly or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

86 people

The number who actually took part.

Started

May 2022

Finished

May 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female diagnosed with FECD. Exclusion Criteria: * Females who are pregnant or lactating. * Any ocular surgery for FECD (e.g., penetrating keratoplasty (PKP), Descemet stripping endothelial keratoplasty (DSEK), Descemet membrane endothelial keratoplasty (DMEK), Descemet stripping automated endothelial keratoplasty (DSAEK), Descemet stripping only (DSO) in the study eye.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fuchs endothelial corneal dystrophy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Fuchs' endothelial dystrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Fuchs endothelial corneal dystrophy

Contacts and locations

Locations

  • Comprehensive Eye Care, Ltd

    Washington, Missouri, 63090, United States

  • Devers Eye Institute

    Portland, Oregon, 97210, United States

  • Fondation Ophtalmologique Adolphe de Rothschild

    Paris, 75019, France

  • Houston Eye Associates

    Houston, Texas, 77025-1697, United States

  • Johns Hopkins University

    Baltimore, Maryland, 21287, United States

  • Mayo Clinic

    Rochester, Minnesota, 55905, United States

  • Medical Research Foundation

    Chennai, Tamil Nadu, 600 006, India

  • Metropolitan Eye Research and Surgery Center

    Palisades Park, New Jersey, 07650, United States

  • Price Vision Group

    Indianapolis, Indiana, 46260, United States

  • Scott Christie and Associates

    Cranberry Township, Pennsylvania, 16066, United States

  • Stein Eye Institution UCLA

    Los Angeles, California, 90095, United States

  • Suven Clinical Research CenterL V Prasad Eye Institute

    Banjara Hills, Telangana, 500034, India

  • Tauber Eye Center

    Kansas City, Missouri, 64111, United States

  • UPMC

    Pittsburgh, Pennsylvania, 15213, United States

  • University Hospital of Saint-Etienne

    Saint-Etienne, 42055, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.